Core Viewpoint - Renhe Pharmaceutical (000650) has received the registration certificate for Entecavir tablets in 2021, which is an oral antiviral drug used for the treatment of hepatitis B infection [1] Company Summary - The company specializes in Entecavir, which selectively inhibits the hepatitis B virus [1] - Entecavir is primarily used for treating adults with active viral replication and persistently elevated serum transaminases, or with histologically active lesions in chronic hepatitis B [1]

Core Viewpoint - The company has received a drug registration certificate for Entecavir tablets in 2021, which is used for the treatment of hepatitis B infection [2]. Company Products - Entecavir is an oral antiviral medication that selectively inhibits the hepatitis B virus, primarily used for treating adults with active viral replication and elevated serum transaminases, or active disease in liver histology [2].

Group 1: Overview of Chikungunya Fever - Chikungunya virus is spreading globally, with 119 countries reporting cases and approximately 5.5 million people at risk of infection [1] - In Foshan, Guangdong Province, over 4,000 confirmed cases have been reported, primarily mild cases [1] Group 2: Symptoms and Treatment - Chikungunya fever is characterized by high fever and severe joint pain, particularly affecting small joints [2] - There is currently no specific treatment or widely used vaccine; management is primarily supportive, focusing on symptom relief [3] Group 3: Market Response and Company Involvement - Investors are inquiring about companies with products related to Chikungunya fever, focusing on mosquito repellent products, testing kits, and antipyretic and analgesic medications [4] - Companies like Rainbow Group, Runben Co., and Weigao Medical have reported an increase in sales of mosquito repellent products [5][6] - Pharmaceutical companies such as Renhe Pharmaceutical and Xinhua Pharmaceutical have indicated they offer products for fever and pain relief [7] Group 4: Testing Products - Companies like Kehua Bio, YHLO Biotech, and Shuoshi Bio have developed testing kits for Chikungunya virus [8] - YHLO Biotech has a rapid screening kit for Chikungunya, currently used for research purposes [8] - The market interest in these companies has led to notable stock price increases since the news of the outbreak [8]

Core Viewpoint - The article discusses the results of drug production supervision inspections conducted by the Jiangxi Provincial Drug Supervision Administration from January to June 2025, highlighting compliance and non-compliance among various pharmaceutical companies [2][3][4]. Summary by Category Inspection Results - A total of 23 pharmaceutical companies were inspected during the first half of 2025, with most companies found to be compliant with the Good Manufacturing Practice (GMP) standards [2][3]. - Specific companies such as Jiangxi Ma Kang Pharmaceutical Co., Ltd. and Jiangxi Chengzhi Yongfeng Pharmaceutical Co., Ltd. were noted for their compliance in producing various drug forms including eye drops and traditional Chinese medicine [2][3]. Compliance Details - Companies like Jiangxi Qinfeng Pharmaceutical Co., Ltd. and Jiangxi Yichuan Pharmaceutical Technology Co., Ltd. were recognized for their adherence to GMP during inspections, covering a range of products from small volume injections to tablets [3][4]. - The inspections included checks on production lines for specific drugs, ensuring that companies met the required safety and quality standards [2][3]. Non-Compliance Issues - Some companies faced issues during inspections, although the article primarily focuses on those that complied with regulations [2][3]. - The inspections aimed to ensure that all pharmaceutical products manufactured in the province meet the necessary legal and quality standards [2][3][4].

Group 1: Chili Pepper Industry in Jiangxi - Jiangxi's chili pepper industry, particularly in Gao'an, has seen significant growth, with an annual planting area of approximately 15,000 acres and a production volume of around 60,000 tons, generating a total output value of about 360 million yuan [1][3] - The implementation of an innovative model involving government guidance, village investment, cooperative operation, and farmer participation has improved the chili pepper supply chain, addressing previous challenges such as product variety and market access [3][4] - The Gao'an chili pepper industry park has created over 300 jobs in surrounding towns and is projected to see a 30% increase in production in 2024, with purchase prices doubling [3][4] Group 2: Traditional Chinese Medicine Industry in Jiangxi - The Renhe Group in Zhangshu City has successfully integrated traditional Chinese medicine with modern health products, achieving significant sales growth, with some products exceeding 100 million yuan in annual sales [5][7] - The company has adapted traditional formulations into more convenient forms, such as tablets and capsules, while reducing sugar content to cater to modern consumer preferences [5][8] - Jiangxi's traditional Chinese medicine industry has established itself as a leading sector in the central region, with a total sales revenue of 16.75 billion yuan in 2024, reflecting a year-on-year growth of 6.42% [8][9]

证券代码：000650 证券简称：仁和药业 公告编号：2025-030 仁和药业股份有限公司 关于公司电子邮箱变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 仁和药业股份有限公司（以下简称 "公司"）根据实际工作需要，对公司 电子邮箱进行变更。为便于投资者与公司联系，现将公司电子邮箱变更情况公 除上述内容变更外，公司联系地址、电话、传真等其他信息均保持不变。 新电子邮箱自本公告披露之日起正式启用，原电子邮箱将不再使用，敬请广大 投资者注意。对此带来的不便，敬请谅解。 特此公告。 仁和药业股份有限公司 董事会 二〇二五年六月一十九日 1 告如下： | 联系方式 | 变更前 | 变更后 | | --- | --- | --- | | 电子邮箱 | rh000650@126.com | rh000650@renhe.com | ...

Group 1 - Over 1500 companies have completed their dividend distribution for the year 2024, with 1532 companies having implemented their dividend plans as of June 9 [2][3] - Companies such as Haibo Sichuang, Lizhu Group, Huate Dain, and Midea Group are among those with the highest proposed dividend amounts per share [2][3] - Midea Group plans to distribute 35 yuan in cash for every 10 shares, with the record date on June 11, 2025, and the payment date on June 12, 2025 [2][3] Group 2 - Renhe Pharmaceutical announced a cash dividend of 1.5 yuan per 10 shares, with the record date on June 16, 2025, and the payment date on June 17, 2025 [3] - Haibo Sichuang plans to distribute a cash dividend of 1.1 yuan per share, with the record date on June 12, 2025, and the payment date on June 13, 2025 [4] Group 3 - Several companies are announcing mid-term dividend plans, with Zhangjiang Hi-Tech proposing to increase mid-term cash dividends based on profitability and cash flow [5][6] - High New Development is seeking authorization to establish a mid-term dividend plan for 2025, emphasizing the need for positive earnings and cash flow [6] Group 4 - The Shanghai Stock Exchange held a meeting to discuss enhancing high dividend and high yield company valuations, indicating a push for increased dividend distributions [7] - Experts suggest that dividends can boost investor confidence and reflect a company's cash strength and profitability [7]

仁和药业股份有限公司 证券代码：000650 证券简称：仁和药业 公告编号：2025-029 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、权益分派方案 本公司2024年年度权益分派方案为：以公司现有总股本剔除已回购股份0股后的 通过深股通持有股份的香港市场投资者、境外机构（含QFII、RQFII）以及持有首发前 限售股的个人和证券投资基金每10股派1.350000元；持有首发后限售股、股权激励限 售股及无限售流通股的个人股息红利税实行差别化税率征收，本公司暂不扣缴个人所 得税，待个人转让股票时，根据其持股期限计算应纳税额【注】；持有首发后限售股、 股权激励限售股及无限售流通股的证券投资基金所涉红利税，对香港投资者持有基金 份额部分按10%征收，对内地投资者持有基金份额部分实行差别化税率征收）。 【注：根据先进先出的原则，以投资者证券账户为单位计算持股期限，持股1个月 （含1个月）以内，每10股补缴税款0.300000元；持股1个月以上至1年（含1年）的， 每10股补缴税款0.150000元；持股超过1年的，不需补缴税款。】 二、权益分派股权登记日与除权 ...

2024年年度权益分派实施公告 证券代码：000650 证券简称：仁和药业 公告编号：2025-029 仁和药业股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、公司 2024 年年度股东大会审议通过的 2024 年年度利润分配预案为：以 2024 年 12 月 31 日 的公司总股本 1,399,938,234 股为基数，向全体股东每 10 股派发现金 1.50 元（含税），不送股不 转增，剩余未分配利润结转下一年度； 2、公司本次实施的分配方案与股东大会审议通过的方案一致； 3、本次实施的分配方案距离股东大会审议通过分配方案的时间未超过两个月； 4、自权益分配方案披露至实施期间公司股本总额未发生变化； 5、在实施权益分派的股权登记日前,公司总股本发生变动的，则以最新总股本为基数，按分配 总额不变的原则对分配比例进行相应的调整。 仁和药业股份有限公司（以下简称"本公司"或"公司"）2024年年度权益分派 方案已获2025年5月23日召开的2024年度股东大会审议通过，股东大会决议公告刊登于 2025年5月24日的《证券日报》《证券 ...

证券代码：000650 证券简称：仁和药业 公告编号：2025-028 仁和药业股份有限公司 第十届监事会第一次会议决议公告 本公司及其董事、监事、高级管理人员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 仁和药业股份有限公司第十届监事会第一次会议通知于 2025 年 5 月 23 日以 送达、电子邮件等方式发出，会议于 2025 年 5 月 26 日以现场与通讯结合方式在 南昌元创国际 18 层公司会议室召开。会议应到监事 5 人，实到监事 5 人，监事 会主席罗晚秋女士主持本次会议，会议符合《公司法》和《公司章程》的有关规 定。经与会监事认真审议，会议审议通过了《关于选举公司第十届监事会主席的 议案》。 附件： 1、罗晚秋，女，汉族，1974年11月出生，本科学历，注册会计师。曾任江 西升科工贸有限公司办公室主任、仁和(集团)发展有限公司财务部长等职务。 现任公司监事会主席、审计考核管理总监、仁和(集团)发展有限公司(本公 司控股股东)董事，与本公司存在关联关系。其本人未直接或间接持有公司股份， 与持有公司5%以上股份的股东、实际控制人、公司其他董事、监事、高级管理 人员不存 ...